OptiTROP-Lung06

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jul 15, 2026 → Oct 28, 2026

Cited window

Sep 23, 2026 → Oct 25, 2026

Retrieved

Oct 29, 2026

Title

A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registry

NCT06711900

Study IDs

SKB264-Ⅲ-14

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

432 estimated

Registered

2024-12-02

Start

2024-10-30 actual

Primary completion

2026-12 estimated

Primary endpoint

Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)

Interventions

4 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –1 matching source (1 X thread) could not be read and is not included.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –The report describes short-form commentary, not an assessment of the complete trial data. Results publications used as trial context are separate from the commentary synthesis. No protocol is listed in the available registry information, and regulatory information is incomplete.
• –Some potentially relevant sources and passages were not fully assessed, including discussions without an explicit trial name; one additional source could not be read. Additional views or qualifications may be missing.
• –Eight posts do not represent eight independent HCP views: two repeat a speaker’s commentary, and reposts are not separate endorsements.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –The immature, exploratory OS analysis, limited toxicity detail and unquantified sex-subgroup observation constrain conclusions about adoption and patient selection.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "OptiTROP-Lung06" (NCT06711900), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "optitrop-lung06-06711900". If you cannot make requests, read https://www.erudio.com/reports/optitrop-lung06-nct06711900.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06711900", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06711900 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/optitrop-lung06-nct06711900.json
curl https://www.erudio.com/reports/optitrop-lung06-nct06711900.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "optitrop-lung06-06711900" })